Seeking Alpha

Celldex Therapeutics (CLDX +25%) goes on a tear today after reporting positive final results...

Celldex Therapeutics (CLDX +25%) goes on a tear today after reporting positive final results from Phase 2b studies of its breast cancer treatment CDX-011. Brean Capital was impressed, saying in a note to clients that the treatment "targets a clear and large unmet need," while Oppenheimer raised its price target from $6 to $8 and Jefferies from $7 to $9.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|